Compare MGIC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | OPK |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 1.0B |
| IPO Year | 1991 | 1995 |
| Metric | MGIC | OPK |
|---|---|---|
| Price | $27.44 | $1.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $18.00 | $2.28 |
| AVG Volume (30 Days) | 37.3K | ★ 3.9M |
| Earning Date | 11-18-2025 | 02-26-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | $603,216,000.00 | ★ $642,067,000.00 |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $33.10 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.36 | $1.11 |
| 52 Week High | $27.44 | $2.04 |
| Indicator | MGIC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 57.15 |
| Support Level | $26.77 | $1.24 |
| Resistance Level | $27.31 | $1.38 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 98.71 | 88.89 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.